Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Commercialization symbols : INCY save search
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XNCR | $18.325 -3.3% 220K
|
Health Technology
|
| O: -1.55%
H: 2.76%
C: 1.84%
MOR | $17.96 -0.5% 72K
|
Health Technology
|
| O: 0.99%
H: 59.84%
C: 54.47%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: -0.6%
H: 0.81%
C: 0.1%
monjuvi global commercialization
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
Published: 2022-01-25 (Crawled : 01:00) - biospace.com/
MRUS | $40.04 -1.06% 230K
|
Health Technology
|
| O: -1.81%
H: 2.56%
C: 1.11%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: -0.73%
H: 0.33%
C: -0.86%
mcla-145 commercialization
Syros Announces Appointment of Conley Chee as Chief Commercial Officer
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
SYRS | $4.525 -4.13% 50K
|
Health Technology
|
| O: 0.0%
H: 3.77%
C: 0.84%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
commercialization
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Published: 2021-09-27 (Crawled : 12:00) - biospace.com/
SNDX | $20.77 1.37% 280K
|
Health Technology
|
| O: 6.0%
H: 0.86%
C: -0.15%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
disease collaboration commercialization
Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of Lisaftoclax (APG-2575) and Equity Investment
Published: 2021-07-14 (Crawled : 18:00) - prnewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.21%
H: 0.61%
C: 0.24%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.24%
H: 0.11%
C: -1.16%
commercialization china
Innovent and Ascentage Pharma Reach Multifaceted Strategic Agreement including Joint Commercialization of Olverembatinib in China, Joint Clinical Development on Multiple Products, and Equity Investment
Published: 2021-07-14 (Crawled : 16:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.21%
H: 0.61%
C: 0.24%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.24%
H: 0.11%
C: -1.16%
commercialization china
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
INSG | $2.98 23.14% 190K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.